$GILD · GILEAD SCIENCES, INC.
Gilead Sciences filed its Q3 2026 10-Q, reporting Q3 revenue of $8.3B (+6.8% YoY) and diluted EPS of $1.94. For the nine months ended September 30, 2026, the company posted a net loss of $6.045B, driven by $11.3B in acquired IPR&D charges (primarily the Q2 acquisitions of Arcellx, Tubulis, and Ouro Medicines) and a $1.75B IPR&D impairment on sacituzumab govitecan-hziy for NSCLC. Total stockholders' equity fell to $12.96B from $22.62B at year-end 2025.
- Q3 2026 revenue $8.3B, +6.8% YoY; product sales $8.29B vs $7.35B in Q3 2025
- Q3 diluted EPS $1.94 vs $2.43 YoY; operating margin 41.7%
- Nine-month net loss $6.045B driven by $11.3B acquired IPR&D and $1.75B IPR&D impairment
- Acquired IPR&D of $11.3B in 9M 2026 includes Arcellx, Tubulis, and Ouro Medicines acquisitions in Q2
- Retained earnings collapsed from $13.73B at Dec 2025 to $3.11B at Sep 2026 after dividends and net loss
Extended-hours trading at $172.44, up 4.12% vs regular close of $165.61. Market appears to be focusing on the clean Q3 beat (revenue +6.8% YoY, operating income $3.46B) rather than the nine-month GAAP loss, which was already known from Q2's acquisition-heavy quarter.
The contrast between strong Q3 operating performance ($3.46B operating income) and the nine-month $6.0B GAAP loss from aggressive M&A illustrates both Gilead's growth ambitions and the execution risk embedded in its pipeline bets.
Gilead's aggressive M&A spend ($11.3B in acquired IPR&D over nine months) mirrors the biopharma sector's hunger for bolt-on oncology and inflammation assets, but the concentrated Q2 deal spree is unusually large even by big-pharma standards.
$1.75B IPR&D impairment on sacituzumab govitecan-hziy for NSCLC in Q2 2026 signals pipeline risk. Retained earnings at just $3.1B after $3.1B in dividends and $6.0B net loss raises questions about dividend sustainability if operating cash flow weakens.